SecSonar.com

Innate Pharma S.A. (IPHA)

Innate Pharma S.A. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Innate Pharma S.A. (IPHA) is a Biotechnology company based in FR with a market capitalization of $182.2M. Revenue declined 77.9% year-over-year and free cash flow was negative at -$58.1M. This page tracks IPHA's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

FR · 181 employees · IPO Oct 17, 2019

Valuation

Valuation & price

$1.76 · as of May 26, 2026 · -25.8% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

—

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$2.31$1.79$1.27Jul 25Dec 25Jun 26Jul 7, 25$1.79Jul 9, 25$1.72Jul 11, 25$1.74Jul 15, 25$1.77Jul 17, 25$1.77Jul 21, 25$1.92Jul 23, 25$1.98Jul 25, 25$2.03Jul 29, 25$2.14Jul 31, 25$2.11Aug 4, 25$2.11Aug 6, 25$2.15Aug 8, 25$2.10Aug 12, 25$2.07Aug 14, 25$2.18Aug 19, 25$2.31Aug 21, 25$2.23Aug 25, 25$2.24Aug 27, 25$2.10Aug 29, 25$2.16Sep 3, 25$2.02Sep 5, 25$2.05Sep 9, 25$2.05Sep 11, 25$2.04Sep 15, 25$2.08Sep 17, 25$2.05Sep 19, 25$1.87Sep 23, 25$1.80Sep 25, 25$1.82Sep 29, 25$1.82Oct 2, 25$2.01Oct 6, 25$1.98Oct 8, 25$2.01Oct 10, 25$2.03Oct 14, 25$2.03Oct 16, 25$2.14Oct 20, 25$2.12Oct 22, 25$2.09Oct 24, 25$2.20Oct 28, 25$2.09Oct 30, 25$1.99Nov 3, 25$1.90Nov 5, 25$1.82Nov 7, 25$1.78Nov 11, 25$2.14Nov 14, 25$1.82Nov 18, 25$1.80Nov 20, 25$1.82Nov 24, 25$1.81Nov 26, 25$1.89Dec 1, 25$1.90Dec 3, 25$1.90Dec 5, 25$1.89Dec 9, 25$1.89Dec 11, 25$1.85Dec 15, 25$1.88Dec 17, 25$1.81Dec 19, 25$1.75Dec 23, 25$1.76Dec 26, 25$1.75Dec 31, 25$1.75Jan 5, 26$1.77Jan 7, 26$1.77Jan 9, 26$1.76Jan 13, 26$1.81Jan 15, 26$1.76Jan 20, 26$1.81Jan 22, 26$1.78Jan 26, 26$1.76Jan 28, 26$1.78Jan 30, 26$1.83Feb 3, 26$1.78Feb 5, 26$1.73Feb 9, 26$1.74Feb 11, 26$1.70Feb 17, 26$1.69Feb 19, 26$1.69Feb 23, 26$1.66Feb 25, 26$1.74Feb 27, 26$1.72Mar 3, 26$1.58Mar 5, 26$1.58Mar 9, 26$1.60Mar 11, 26$1.55Mar 13, 26$1.50Mar 17, 26$1.34Mar 19, 26$1.27Mar 23, 26$1.37Mar 25, 26$1.28Mar 27, 26$1.30Apr 1, 26$1.35Apr 6, 26$1.39Apr 8, 26$1.45Apr 10, 26$1.41Apr 14, 26$1.63Apr 16, 26$1.62Apr 20, 26$1.59Apr 22, 26$1.43Apr 24, 26$1.41Apr 28, 26$1.40Apr 30, 26$1.44May 4, 26$1.43May 6, 26$1.51May 8, 26$1.41May 12, 26$1.36May 15, 26$2.02May 19, 26$2.03May 21, 26$1.97May 26, 26$1.72May 28, 26$1.74Jun 1, 26$1.78Jun 3, 26$1.76Jun 5, 26$1.71Jun 9, 26$1.77Jun 11, 26$1.74Jun 15, 26$1.79Jun 17, 26$1.78Jun 22, 26$1.81Jun 24, 26$1.90Jun 30, 26$1.90
$1.1752-week range$2.38
Loading valuation history…

Fundamentals

Key fundamentals

$182.2M

Market cap

-77.9%

Revenue growth (YoY)

100.0%

Gross margin

-$58.1M

Free cash flow (USD)

-$11.7M

Net debt

Net cash position

10.3%

Share dilution

0/4

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$56.2MFY 2017$32.6MFY 2018$79.9MFY 2019$69.0MFY 2020$69.8MFY 2021$12.1MFY 2022$57.7MFY 2023$51.9MFY 2024$12.6MFY 2025$2.8M
$56.2M$2.8M

Free cash flow by year

2016 → 2025

FY 2016$-46.2MFY 2017$-54.1MFY 2018$-34.0MFY 2019$-30.5MFY 2020$-63.1MFY 2021$-59.8MFY 2022$-20.3MFY 2023$-34.9MFY 2024$-7.3MFY 2025$-50.8M
-$46.2M-$50.8M

Gross margin by year

2021 → 2025

FY 2021-184.1%FY 202210.4%FY 202310.8%FY 2024100.0%FY 2025100.0%
-184.1%100.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 6-K filed May 13, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 6-K filingAnnual General Meeting ResultsMay 22, 2026Filing
  • 6-K filingConference ParticipationMay 19, 2026Filing
  • Quarterly reportQuarterly Report FiledMay 13, 2026Filing
  • 6-K filingVoting Rights UpdateMay 12, 2026Filing
  • Quarterly reportQuarterly Report FiledMay 6, 2026Filing
  • 6-K filingInvestor Conference ParticipationApr 23, 2026Filing
  • 6-K filingClinical Trial Results PresentationApr 17, 2026Filing
  • 6-K filingAnnual General Meeting NoticeApr 13, 2026Filing
  • 6-K filingVoting Rights UpdateApr 13, 2026Filing
  • 6-K filingPresentation AnnouncementApr 8, 2026Filing

Questions

Frequently asked questions

What is Innate Pharma S.A.'s market cap?

Innate Pharma S.A. (IPHA) has a market capitalization of $182.2M.

What is IPHA's P/E ratio?

A meaningful P/E ratio is not available for IPHA — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

Are insiders buying IPHA stock?

SEC Form 4 filings show no open-market insider buys at Innate Pharma S.A. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

SRZN

Surrozen, Inc.

$184.8M

AVTX

Avalo Therapeutics, Inc.

$179.1M

IFRX

InflaRx N.V.

$175.9M

ARTV

Artiva Biotherapeutics, Inc.

$193.8M

PLX

Protalix BioTherapeutics, Inc.

$170.4M

PRQR

ProQR Therapeutics N.V.

$168.6M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.